Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater weight loss (up to 20.9%) compared to selective GLP-1 receptor agonists (e.g., semaglutide) by activating both GIP and GLP-1 signaling pathways in the brain and peripheral tissues.
If you have obesity and lifestyle changes alone haven't worked, a dual GIP/GLP-1 agonist like tirzepatide (Mounjaro/Mounjaro) is currently one of the most effective medical treatments available. It is taken as a once-weekly injection and can lead to nearly 21% body weight loss in clinical trials, which is significantly higher than older GLP-1 drugs. Be prepared for potential mild stomach issues during the first few months as your dose increases, but these often subside. This treatment is intended for adults with obesity or overweight with at least one weight-related condition.
Tirzepatide, a novel glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor (GLP-1R) agonist, resulted in greater weight reduction than selective GLP-1R agonists by affecting tissues not targeted by selective GLP-1R agonists, and by activating and integrating both GIP and GLP-1R signaling pathways in the brain [24]. Tirzepatide treatment in obese patients induced significant and sustained weight loss of up to approximately 20% [25].
Why this rating
Based on large-scale, randomized, double-blind, placebo-controlled clinical trials (SURMOUNT-1) with substantial sample sizes (n=2539).
Source
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Eun Roh et al. · International Journal of Molecular Sciences · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →